SCM
KROS icon

Stonepine Capital Management’s Keros Therapeutics KROS Stock Holding History

Stonepine Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$1.02M – 74
2025
Q1 		$1.02M Buy
+100,000
New +$1.16M 0.99% 22

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Stonepine Capital Management's KROS Position: Q2 2025 in Review

Stonepine Capital Management sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 100,000 shares — an estimated $1.02M sold.

Stonepine Capital Management first reported a position in KROS in Q1 2025 and held it in 1 quarter. The position peaked at $1.02M in Q1 2025. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Stonepine Capital Management reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 100,000 Keros Therapeutics shares in Q2 2025, an estimated $1.02M.
  • Stonepine Capital Management first reported a position in Keros Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Keros Therapeutics position peaked at $1.02M in Q1 2025.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.